Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Read Why Barclays Analyst Is 'Negatively Biased' On Kodiak Sciences

Barclays has lowered the firm's price target on Kodiak Sciences Inc (NASDAQ:KOD) to $50 from $81 and keeps an Underweight rating on the shares, representing an almost 20% downside.

  • The analyst dropped the price target to reflect a lower probability of success and lower peak penetrations.
  • After conducting a "deep dive" ahead of the "binary catalyst: of the KSI- 301 Phase 2/3 DAZZLE study in wet macular degeneration in late Q1, analyst Gena Wang continues to be "negatively biased." 
  • Last week, the Company completed enrollment in its GLEAM and GLIMMER Phase 3 trials of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate, in diabetic macular edema (DME). 
  • The Company says topline data from the DAZZLE trial is expected this quarter and mid-year for BEACON.
  • KSI-301 is an investigational anti-VEGF therapy built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform. It is designed to maintain potent and effective drug levels in ocular tissues for longer than available agents. 
  • Price Action: KOD shares are down 0.26% at $63.62 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.